N/A
N=194
Rural Tailored COVID-19 Communication to Promote SARS-CoV-2 Antibody Testing in Saliva
SARS-CoV2 Infection
Bottom Line
View on ClinicalTrials.gov: NCT06085547 ↗Enrolled (actual)
194
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcome: Primary: Number (Percentage) of Participants Requested to Participate in Home-based Saliva-based SARS-CoV-2 Antibody Testing. — 91; 88 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- General SARS-CoV-2 Communication (Behavioral); Rural-Targeted SARS-CoV-2 Communication (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Michigan State University
- Primary completion
- Nov 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number (Percentage) of Participants Requested to Participate in Home-based Saliva-based SARS-CoV-2 Antibody Testing. |
91; 88 | — |
| PRIMARY Number (Percentage) of Participants Who Completed Home-based Salivary Antibody Testing. |
77; 70 | — |
| PRIMARY Theory of Planned Behavior Antibody Testing Outcomes |
5.97; 5.97; 4.01; 3.85; 6.06; 6.02 | — |
| PRIMARY Antibody Testing Rural-Adapted Anticipatory Racism |
1.63; 2.18 | — |
Summary
This study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among individuals residing in rural Northern Michigan. This iteration will consider individuals recruited from rural Northern Michigan and assess individuals' willingness to participate in home-based saliva sample collections.
Eligibility Criteria
Inclusion Criteria
- White, 18 or older
Exclusion Criteria
- All who do not meet inclusion criteria
Data sourced from ClinicalTrials.gov (NCT06085547). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.